MGMT and glioblastoma: Due to its effect on TMZ therapeutic response, MGMT promoter methylation status is a strong prognostic predictor of disease progression and overall survival [17], and, with the almost universal use of TMZ in the treatment of GBM at the present time, recent efforts have explored whether additional clinicopathological characteristics may be combined with MGMT promoter methylation to improve prognostic predictions [6].